Repurposing Approach Identifies Auranofin with Broad Spectrum Antifungal Activity That Targets Mia40-Erv1 Pathway by Shankar Thangamani et al.
ORIGINAL RESEARCH
published: 18 January 2017
doi: 10.3389/fcimb.2017.00004
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 1 January 2017 | Volume 7 | Article 4
Edited by:
Martin G. Klotz,
Queens College (CUNY), USA
Reviewed by:
Derek Sullivan,
Dublin Dental University Hospital,
Ireland
Joy Scaria,
South Dakota State University, USA
Tavan Janvilisri,
Mahidol University, Thailand
*Correspondence:
Tony R. Hazbun
thazbun@purdue.edu
Mohamed N. Seleem
mseleem@purdue.edu
Received: 04 August 2016
Accepted: 03 January 2017
Published: 18 January 2017
Citation:
Thangamani S, Maland M,
Mohammad H, Pascuzzi PE,
Avramova L, Koehler CM, Hazbun TR
and Seleem MN (2017) Repurposing
Approach Identifies Auranofin with
Broad Spectrum Antifungal Activity
That Targets Mia40-Erv1 Pathway.
Front. Cell. Infect. Microbiol. 7:4.
doi: 10.3389/fcimb.2017.00004
Repurposing Approach Identifies
Auranofin with Broad Spectrum
Antifungal Activity That Targets
Mia40-Erv1 Pathway
Shankar Thangamani 1, Matthew Maland 2, Haroon Mohammad 1, Pete E. Pascuzzi 3, 4,
Larisa Avramova 5, Carla M. Koehler 2, Tony R. Hazbun 5, 6* and Mohamed N. Seleem 1, 7*
1Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA,
2Department of Chemistry and Biochemistry and the Molecular Biology Institute, University of California, Los Angeles, Los
Angeles, CA, USA, 3 Purdue University Libraries, Purdue University, West Lafayette, IN, USA, 4Department of Biochemistry,
Purdue University, West Lafayette, IN, USA, 5 Bindley Bioscience Center, Purdue University, West Lafayette, IN, USA,
6Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette,
IN, USA, 7 Purdue Institute for Inflammation, Immunology, and Infectious Diseases, West Lafayette, IN, USA
Current antifungal therapies have limited effectiveness in treating invasive fungal
infections. Furthermore, the development of new antifungal is currently unable to
keep pace with the urgent demand for safe and effective new drugs. Auranofin,
an FDA-approved drug for the treatment of rheumatoid arthritis, inhibits growth of
a diverse array of clinical isolates of fungi and represents a new antifungal agent
with a previously unexploited mechanism of action. In addition to auranofin’s potent
antifungal activity against planktonic fungi, this drug significantly reduces the metabolic
activity of Candida cells encased in a biofilm. Unbiased chemogenomic profiling, using
heterozygous S. cerevisiae deletion strains, combined with growth assays revealed
three probable targets for auranofin’s antifungal activity—mia40, acn9, and coa4. Mia40
is of particular interest given its essential role in oxidation of cysteine rich proteins
imported into the mitochondria. Biochemical analysis confirmed auranofin targets the
Mia40-Erv1 pathway as the drug inhibited Mia40 from interacting with its substrate,
Cmc1, in a dose-dependent manner similar to the control, MB-7. Furthermore, yeast
mitochondria overexpressing Erv1 were shown to exhibit resistance to auranofin as an
increase in Cmc1 import was observed compared to wild-type yeast. Further in vivo
antifungal activity of auranofin was examined in a Caenorhabditis elegans animal model
of Cryptococcus neoformans infection. Auranofin significantly reduced the fungal load
in infected C. elegans. Collectively, the present study provides valuable evidence that
auranofin has significant promise to be repurposed as a novel antifungal agent and may
offer a safe, effective, and quick supplement to current approaches for treating fungal
infections.
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INTRODUCTION
Invasive fungal infections, particularly those caused by Candida
and Cryptococcus, aﬄict millions of patients annually resulting
in more than 1,350,000 deaths despite the introduction of new
antifungal agent (Brown et al., 2012; Pfaller, 2012; Perlin, 2015;
Perlin et al., 2015; Sanguinetti et al., 2015). Unfortunately,
current antifungal therapies have limited effectiveness in treating
invasive fungal infections and suffer from restrictions in route of
administration, spectrum of activity, and bioavailability in target
tissues such as the brain (Brown et al., 2012; Vandeputte et al.,
2012). Further compounding this problem, the development
of new antifungal is currently unable to keep pace with the
urgent demand for safe and effective new drugs. Hence, there
is a pressing and urgent need for novel, inexpensive, and safe
antifungal drugs to combat these dangerous pathogens.
The concept of drug repositioning has recently gained
momentum and emerged as a viable approach to expedite
anti-infective drug development (Butts and Krysan, 2012;
Thangamani et al., 2015a,b,c). For example, several reports
have demonstrated that auranofin, an orally bioavailable FDA-
approved drug for treatment of rheumatoid arthritis, exhibits
potent antibacterial and antiparasitic activities (Jackson-Rosario
et al., 2009; Debnath et al., 2012; Cassetta et al., 2014; Hokai et al.,
2014; Aguinagalde et al., 2015; Thangamani et al., 2016a,b). This
discovery led to the FDA granting auranofin Orphan Drug status
for treatment of amebiasis. Auranofin is currently approved
for long-term treatment of unresponsive rheumatoid arthritis;
it is the first, and only, gold compound to be administered
orally (Bernhard, 1982; Furst et al., 1983). Although auranofin
is slightly less effective than parenteral gold compounds for
treatment of rheumatoid arthritis, auranofin’s oral bioavailability
and reduced associated side effects offer significant advantages
over traditional injectable gold drugs (Bernhard, 1982; Furst
et al., 1983). Although auranofin has been used clinically for
almost 30 years, its mechanism of action (MOA) in treating
unresponsive rheumatoid arthritis is still poorly understood
(Shaw, 1999; Berners-Price and Filipovska, 2011). The emergence
of new anti-rheumatoid drugs with fewer side effects and
faster activity has resulted in the decline of oral gold therapy
clinically (Berners-Price and Filipovska, 2011). Nevertheless,
there has been considerable research efforts employed to identify
alternative therapeutic applications for auranofin, particularly in
the area of infectious diseases (Shapiro andMasci, 1996; Lobanov
et al., 2006; Kuntz et al., 2007; Bonilla et al., 2008; Sannella
et al., 2008; Angelucci et al., 2009; Chomont et al., 2009; Jackson-
Rosario et al., 2009; Lewis et al., 2011; Caroli et al., 2012; Debnath
et al., 2012; Ilari et al., 2012; Chirullo et al., 2013; Tejman-Yarden
et al., 2013; Sharlow et al., 2014).
Recent studies by Fuchs et al. (2016) and Stylianou et al.
(2014) reported that auranofin also possesses antifungal
activity. However, the antifungal MOA and in vivo antifungal
efficacy of auranofin remain unclear with several possible
targets reported. Thus, the objectives of our study were to
determine the antifungal activity of auranofin against clinical
isolates of different fungal pathogens, to investigate the
drug’s antibiofilm activity, to deduce auranofin’s antifungal
MOA using an unbiased chemogenomic approach, and to
validate the drug’s in vivo antifungal efficacy in a Cryptococcus
neoformans-infected Caenorhabditis elegans whole animal
model.
MATERIALS AND METHODS
Fungal Strains and Reagents
Fungal strains used in this study are presented in Table 1.
Yeast peptone dextrose agar (YPD) was purchased from BD
Biosciences (San Jose, CA). Auranofin (Enzo Life Sciences,
Farmingdale, NY), fluconazole (Acros Organics, New Jersey),
and flucytosine (TCI chemicals, Tokyo, Japan) were purchased
from commercial vendors. XTT-sodium salt, menadione, RPMI
powder, and MOPS were purchased from Sigma-Aldrich (St.
Louis, MO). Concanavalin A–conjugated with FITC 488 dye was
acquired from Thermo Fisher Scientific Inc. (Waltham, MA).
Antifungal Susceptibility Testing
Antifungal susceptibility testing was carried out as per the
National Committee for Clinical Laboratory Standards M-27A3
(NCCLS) guidelines (da Silva et al., 2016). Briefly, the inocula
were prepared from 24 h old cultures of Candida spp. or 48 h
old cultures of Cryptococcus spp. in YPD plates. Five colonies
were then transferred to 5mL of sterile 0.9% saline (PBS). The
suspensions were adjusted to McFarland standard 0.5 and then
diluted 1:2000 in RPMI 1640 buffered to pH 7.0 with 0.165M
MOPS (RPMI-MOPS) to yield an inoculum of 5.0 × 102,
−2.5 × 103 CFU/mL. An aliquot (100µL) of the resulting
suspension was incubated with serially diluted fluconazole,
flucytosine, and auranofin for 24 h for Candida spp and 72 h
for Cryptococcus spp. The minimum inhibitory concentration
(MIC) of fluconazole and flucytosine were determined as the
prominent decrease (∼50%) in visible growth compared to
untreated controls, as per NCCLS guidelines. Similarly the
MIC of auranofin was determined as the lowest concentration
resulting in 50% reduction in visible growth. All experiments
were carried out in triplicate wells.
Time Kill Assay
Fungal cultures of Candida albicans and Cryptococcus
neoformans were diluted approximately to 5 × 105 CFU/mL and
treated with 5 × and 10 × MICs of auranofin and fluconazole
(in triplicate) in RPMI-MOPS, at 35◦C. Samples were collected
at indicated time points and serially diluted in PBS and plated
onto YPD plates. Plates were incubated at 35◦C for 24–48 h prior
to counting fungal colony forming units (CFU), as described
elsewhere (Cantón et al., 2004).
XTT-Reduction Assay
C. albicans ATCC 10231 was grown in YPD broth at 35◦C for
24 h. Cells were washed with PBS and resuspended in RPMI-
MOPS at 106 cells/mL (Pierce et al., 2008; Rane et al., 2012). An
aliquot (100µL) of cell suspension was transferred to wells in
a 96-well tissue culture plate. After 48 h incubation (at 37◦C),
wells were washed with PBS and drugs (auranofin, fluconazole,
and flucytosine) were added at indicated concentrations. After
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TABLE 1 | MIC of auranofin and control antifungal drugs against Candida and Cryptococcus strains.
Strains Description Auranofin
(µg/ml)
Fluconazole
(µg/ml)
Flucytosine
(µg/ml)
C. albicans NR 29434 Bloodstream isolate from a person with a bloodstream infection collected in
Winnipeg, Manitoba, Canada, in 2000
8 4 0.125
C. albicans ATCC 10231 Isolated from a man with bronchomycosis 2 2 0.25
C. albicans NR 29449 Is a vaginal isolate from a person with vaginitis collected in Ann Arbor, Michigan,
USA, between 1990 and 1992
8 2 4
C. albicans NR 29435 Is a bloodstream isolate from a person with a bloodstream infection collected in
Iowa City, Iowa, USA, in 2000
1 4 0.0625
C. albicans NR 29448 Is an isolate from a person with a bloodstream infection, collected in Arizona, USA. 4 >64 0.0625
C. albicans NR 29437 Is a bloodstream isolate from a person with a bloodstream infection collected in
Brussels, Belgium in 2000
4 2 0.0625
C. albicans NR 29446 Is a bloodstream isolate from a person with a bloodstream infection collected in
Utah, USA.
16 >64 0.25
C. albicans NR 29453 Is an oral isolate from an HIV+ person collected in Pretoria, South Africa 8 2 0.0625
C. albicans NR 29438 Is a bloodstream isolate from a person with a bloodstream infection, collected in
Tel-Hashomer, Israel, in 2000.
16 2 0.0625
C. albicans ATCC 26790 Pulmonary candidiasis 8 2 0.0625
C. albicans ATCC 24433 Nail infection 8 4 1
C. albicans ATCC 14053 Human blood, Bethesda, MD 8 4 0.125
C. albicans ATCC 90028 Blood, Iowa 16 4 1
C. albicans NR 29366 Human isolate collected in China 16 >64 0.0625
C. albicans NR 29367 Human isolate collected in China. 16 >64 0.0625
C. glabrata ATCC MYA-2950 – 8 4 0.0625
C. glabrata ATCC 66032 – 8 2 0.0625
C. tropicalis ATCC 13803 – 16 2 0.125
C. tropicalis ATCC 1369 – 4 1 0.25
C. parapsilosis ATCC 22019 Case of sprue, Puerto Rico 4 1 0.25
C. neoformans NR-41291 Obtained from human cerebrospinal fluid in China in July 2011. 4 1 0.5
C. neoformans NR-41292 Obtained from human cerebrospinal fluid in China in February 2012. 0.5 1 0.5
C. neoformans NR-41296 Obtained from human cerebrospinal fluid in China in February 2012. 1 2 0.5
C. neoformans NR-41295 Obtained from human cerebrospinal fluid in China in February 2012. 4 2 0.5
C. neoformans NR-41294 Obtained from human cerebrospinal fluid in China in June 2011. 0.5 4 2
C. neoformans NR-41297 Obtained from human cerebrospinal fluid in China in February 2012. 1 8 4
C. neoformans NR-41298 Obtained from human cerebrospinal fluid in China in February 2012. 1 4 2
C. neoformans NR-41299 Obtained from human cerebrospinal fluid in China in August 2009. 4 4 2
C. neoformans NR-41291 Obtained from human cerebrospinal fluid in China in July 2011. 1 4 1
Cryptococcus gattii—CBS1930 Isolated from a goat in Aruba prior to the outbreak in Vancouver, British Columbia,
Canada.
0.5 2 2
Cryptococcus gattii—R265 Isolated from a human on Vancouver Island, Canada during the outbreak that
began in the late 1990’s
1 1 1
Cryptococcus gattii—Alg40 Progeny of a genotypic cross between C. gattii strains R265 and CBS1930. 0.5 2 0.5
Cryptococcus gattii—Alg75 Progeny of a genotypic cross between C. gattii strains R265 and Alg40. 8 8 8
Cryptococcus gattii—Alg81 Progeny of a genotypic cross between C. gattii strains R265 and Alg75. 4 8 4
Cryptococcus gattii—Alg99 Progeny of a genotypic cross between C. gattii strains R265 and Alg81. 4 8 4
Cryptococcus gattii—Alg114 Progeny of a genotypic cross between C. gattii strains R265 and Alg99. 8 8 4
Cryptococcus gattii—Alg115 Progeny of a genotypic cross between C. gattii strains R265 and Alg114. 8 8 4
Cryptococcus gattii—Alg127 Progeny of a genotypic cross between C. gattii strains R265 and Alg115. 4 4 4
24 h of incubation, the supernatant was removed and 100µL
of XTT/menadione solution was added to each well. The
plates were covered with aluminum foil and incubated at 37◦C
for 1 h. Aliquots (75µL) were taken from each well and the
absorbance (OD495) was measured using a spectrophotometer.
The antifungal activity of each drug was expressed as a
percentage of metabolic activity of treatment groups relative
to the DMSO-treated control groups. The experiment was
performed using triplicate samples for each treatment
regimen.
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Confocal Imaging of Fungal Biofilms
C. albicans ATCC 10231 was seeded on FBS-coated glass cover
slips in 6-well tissue-culture plates and grown in RPMI-MOPS
medium with 0.2% glucose at 37◦C (Dongari-Bagtzoglou et al.,
2009). After 48 h, wells were washed with PBS and drugs
(auranofin, fluconazole, and flucytosine) were added at indicated
concentrations. After 24 h of treatment, wells were washed with
PBS and stained with concanavalin A–conjugated with FITC 488
dye (25µg/mL in PBS) for 45 min at 37◦C. After incubation, the
coverslips were washed three times with PBS and mounted on
glass slides. Stained biofilms were observed using Leica confocal
laser scanning microscopy. Images were reconstructed using
IMARIS software.
Chemogenomics Profiling of
Saccharomyces cerevisiae
Initial testing of Saccharomyces cerevisiae sensitivity to auranofin
was performed with the wild-type BY4743 diploid strain, the
isogenic parent to the heterozygous diploid deletion collection.
BY4743 was grown in YPD in 96-well plates with 1% DMSO
or auranofin in concentrations ranging from 10 to 200µM
to determine a suitable level of growth inhibition. Auranofin
(75µM) was used for haploinsufficiency profiling because it
delayed growth by 30% compared to the no drug control half-
maximal optical density (OD). All experiments were performed
at 30◦C and cultures were shaken at 300 rpm. The heterozygous
deletion set was purchased in a pooled format (Thermo Fisher
Scientific, Waltham, MA). A frozen aliquot (200µL) was thawed
and used to inoculate 2 mL of YPD and grown for 9 h to reach
an OD600 of 4.0. The culture was diluted to an OD600 of 0.13
and either 1% DMSO or 75µM auranofin was added (three
replicates each, 1mL) and grown for 7 h. The cultures were grown
again by diluting to an OD of 0.13 in 1mL YPD with DMSO
or 60µM auranofin and grown for 8 h. Cultures were harvested
and genomic DNA extracted using the YeaStar Genomic DNA
kit (Zymo Research, Irvine, CA). The UPTAGs were amplified by
PCR with Phusion Hot Start II High-Fidelity DNA polymerase
at 0.02 U/µL (Thermo Fisher Scientific, Waltham, MA) using
0.5 ng/µL genomic DNA. Primers are listed (Table S1). The PCR
reactions were electrophoresed on an agarose gel and the 267 bp
product extracted using a QIAquick Gel Extraction Kit (Qiagen,
Valencia, CA). Purified DNA was measured using a Qubit
instrument and samples were normalized andmixed together to a
final concentration of 10 nM. Strains were grown andmaintained
on media according to standard practices (Amberg et al., 2005).
The pooled PCR products were sequenced using standard
Illumina sequencing in a HiSeq 2500 instrument. The reads
were separated based on a 5 base multiplex tag unique for each
experiment and an average of 5 million reads per replicate was
obtained. The UPTAG barcodes in each experimental sample
were separated based on a reference database of recharacterized
barcode sequences (Smith et al., 2009).
The resulting strain counts were imported into R and analyzed
with edgeR (Robinson et al., 2010). Sequencing library sizes were
normalized using the default parameters. Only strains with one
or more counts in three or more samples were analyzed further.
Differential representation of strains was determined using
the quantile-adjusted conditional maximum likelihood (qCML)
method. False discovery rates were determined to control for
multiple testing.
Saccharomyces Deletion Strain
Haploinsufficiency Validation
Overnight grown yeast cells were diluted (OD600 ∼ 0.03)
and grown in the presence and absence of auranofin, at
indicated concentrations. Growth was monitored using a
spectrophotometer (OD600) at indicated time points and the
results were expressed as percent growth rate for each strain
compared to the untreated control group. To assess growth on
solid medium, 5µL of ten-fold diluted yeast cells were spotted
onto YPD agar containing DMSO or auranofin (6.25µg/mL).
Growth of yeast strains was monitored after incubating the plates
for 48 h, as described elsewhere (Gamberi et al., 2015).
Oxygen Consumption and Membrane
Potential Measurements
Mitochondria were purified from yeast cells grown on YPEG as
described previously (Hasson et al., 2010). Oxygen consumption
measurements with isolated mitochondria were performed
using an oxygen electrode (Hansatec) as described previously
(Dabir et al., 2013). Membrane potential measurements of
purified mitochondria were performed with fluorescent 3, 3′-
dipropylthiadicarbocyanine iodide dye [DiSC3(5)]. 1% DMSO,
carbonyl cyanide m-chlorophenyl hydrazone (CCCP), MB-6,
or MB-7 was added to mitochondria in import buffer (0.6M
sorbitol, 2mM KH2PO4, 60mM KCl, 50mM HEPES-KOH,
5mMMgCl2, 2.5mMEDTA, 5mML-methionine, pH 7.1) for 10
min. Subsequently 0.2µMDiSC3(5) in import buffer was added,
incubated for 5 min, and fluorescence was measured at excitation
and emission length of 620 and 670 nm, respectively.
Purification of Mitochondria
Mitochondria were purified from wild-type yeast or yeast
overexpressing Erv1 with a hexahistidine tag ([a2up] Erv1)
grown in YPEG as described previously (Glick and Pon, 1995;
Dabir et al., 2007). Yeast cultures were kept at 25◦C with
vigorous shaking during growth. Mitochondria concentration
was measured by BCA assay and stored at 25 mg/mL at −80◦C.
Mitochondria with increased levels of Erv1 were purified from a
strain in which Erv1 was overexpressed from a 2-micron plasmid
(Dabir et al., 2007).
Import of Radiolabeled Proteins into Yeast
Mitochondria
Prior to import into purified mitochondria, [35S]-methionine
and cysteine labeled proteins were generated with TNT Quick
Coupled Transcription/Translation kits (Promega) and plasmids
carrying the genes of interest. Transcription of genes was driven
by either a T7 or SP6 promoter. Import reactions were conducted
as previously described (Hasson et al., 2010; Dabir et al., 2013).
After frozen mitochondria aliquots were thawed and added
to the import buffer at a final concentration of 100µg/mL,
1% DMSO or the small molecule was added as indicated. A
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final concentration of 1% DMSO was used in all experiments.
Following incubation at 25◦C for 15 min, import reactions were
initiated by the addition of 5–10µl of translation mix. Aliquots
were removed at intervals during the reaction time course and
import was terminated with addition either of cold buffer or
25µg/mL trypsin, or the combination. If trypsin was added to
digest non-imported precursor protein, soybean trypsin inhibitor
was subsequently added in excess after 15 min incubation on
ice. After a final recovery of by centrifugation (12,000 × g, 6
min), mitochondria were disrupted in Laemmli sample buffer.
Samples from import reaction time points were resolved by
SDS-PAGE and visualized by autoradiography. For experiments
to investigate the Cmc1-Mia40 intermediate, non-reducing
conditions were used. The import reactions were stopped
in the presence of 20mM iodoacetamide and mitochondria
disrupted in Laemmli sample buffer lacking β-mercaptoethanol.
The imported products were separated by non-reducing
SDS-PAGE.
Caenorhabditis elegans (C. elegans)
Infection Study
L4-stage worms of C. elegans AU37 (sek-1; glp-4) strain (glp-
4(bn2) were used to examine the antifungal efficacy of auranofin
as described elsewhere (Mylonakis et al., 2002; Thangamani
et al., 2015d). Briefly, L4-stage worms were infected with C.
neoformans NR-41292 for 2 h at room temperature. After
infection, worms were washed with M9 buffer and treated either
with DMSO or drugs (auranofin, fluconazole, and flucytosine), at
a concentration of 8µg/mL. After 24 h, worms were washed with
PBS and disrupted using silicon carbide particles (Thangamani
et al., 2015d). The final suspensions were plated onto YPD
agar plates containing ampicillin (100µg/mL), streptomycin
(100µg/mL), and kanamycin (45µg/mL) to determine the
colony forming unit (CFU) per worm (Li et al., 2013).
Statistical Analyses
Statistical analyses were done using GraphPad Prism 6.0
(GraphPad Software, La Jolla, CA). P values were calculated via
the Student t-test and P-values of≤0.05 were deemed significant.
RESULTS
Antifungal Activity and Killing Kinetics of
Auranofin
The antifungal activity of auranofin was tested against various
clinical isolates of Candida and Cryptococcus. Auranofin was
very active in inhibiting the growth of all strains of C. albicans,
C. glabrata, C. tropicalis, and C. parapsilosis with the MIC
ranging from 1 to 16µg/ml (Table 1). Auranofin also displayed
potent activity against both C. neoformans and Cryptococcus
gattii inhibiting growth of these fungal species at a concentration
ranging from 0.5 to 8µg/ml (Table 1).
A time-kill assay was employed to investigate the killing
kinetics of auranofin against both C. albicans and C. neoformans.
Similar to fluconazole, auranofin (at the 5 × MIC) exhibited
fungistatic activity against C. albicans ATCC 10231 and
C. neoformans NR-41296 (Figure 1). However, at the 10 ×MIC,
auranofin and fluconazole exhibited fungistatic activity against
C. albicans ATCC 10231, whereas unlike fluconazole, auranofin
(at the 10×MIC) completely kills C. neoformansNR-41296 after
48 h of incubation (Figure 1).
Antibiofilm Activity of Auranofin
The antibiofilm activity of auranofin, against C. albicans, was
evaluated using the XTT reduction assay in order to measure the
metabolic activity of fungal cells post-treatment. The metabolic
activity of C. albicans was reduced by more than 70% with the
treatment of auranofin at 8 × MIC (Figure 2A). However, the
control antifungals fluconazole and flucytosine were ineffective
(less than 10% reduction observed) at reducing metabolic activity
of C. albicans biofilm, even at a concertation equivalent to
32 ×MIC when compared to the DMSO-treated control groups
(Figure 2A).
The effect of auranofin on reducing fungal biofilm density
was further evaluated using confocal microscopy. Fungal cells
stained with ConA conjugated with FITC revealed that auranofin
(8 × MIC) eradicates a considerable portion of Candida cells
in comparison to the control group (Figure 2B). However,
treatment with fluconazole and flucytosine, even at 32 × MIC,
appear similar to control group (Figure 2B). These results
correlate with the results of the XTT reduction assay.
FIGURE 1 | Killing kinetics of auranofin. An overnight culture of C. albicans ATCC 10231 and C. neoformans NR-41291 were treated with 5 × and 10 × MIC of
auranofin and fluconazole (in triplicate) in RPMI-MOPS and incubated at 35◦C. Samples were collected at indicated time points and plated onto YPD plates. Plates
were incubated for 24–48 h prior to counting the colony forming units (CFU).
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FIGURE 2 | Effect of auranofin on Candida biofilms. (A) C. albicans ATCC 10231 biofilm was treated with indicated concentrations of auranofin, fluconazole, and
flucytosine for 24 h. The percent metabolic activity of fungal cells in biofilms, after treatment, was determined using the XTT reduction assay. Results are presented as
means ± SD (n = 3). Statistical analysis was calculated using the two-tailed Student’s t-test. P-values (**P ≤ 0.01) are considered as significant. Auranofin was
compared both to controls and antifungal drugs (**). (B) C. albicans ATCC 10231 biofilm was formed on FBS-coated glass cover slips and treated with indicated
drugs for 24 h and stained with concanavalin A– conjugated with FITC dye and imaged by Leica confocal laser scanning microscopy.
Chemogenomic Profiling Identifies Mia40
As a Potential Target of Auranofin
To investigate the MOA, we subjected auranofin to
chemogenomic profiling using the S. cerevisiae heterozygous
deletion collection. Haploinsufficiency profiling (HIP) allows
for the simultaneous assessment of the sensitivity of the pooled
genome-wide set of heterozygous deletion strains because each
strain is uniquely identified with a synthetic DNA barcode. The
method is an unbiased approach to survey the genome-wide
strain set in order to identify the strains with the most sensitivity
to auranofin. We first identified the concentration that reduced
wild-type growth by 30% and used 75µM to profile the pooled
heterozygous strains in biological samples. PCR was used to
amplify the unique UPTAG DNA barcodes located at the gene
deletion site andwe tracked the barcode abundance with Illumina
sequencing. The resulting counts were normalized and visualized
using EdgeR (Figure 3A). We identified 85 heterozygous
deletion strains that were under-represented based on an FDR
≤ 0.1 when comparing auranofin treatment to DMSO. These
85 strains were analyzed to identify associated gene ontology
cellular component annotations and found to be enriched in
several categories including the mitochondrial intermembrane
space and chromatin components (Supplementary data excel
file). Five heterozygous deletion strains within these enriched
categories (mia40∆, acn9∆, coa4∆, rad18∆, and nsi1∆) were
selected to validate sensitivity to auranofin using a variety
of growth assays (Figure 3A). These strains were randomly
selected on the basis that they represented genes in the highest
significance gene ontology categories including “regulation of
translational initiation” (p-value = 0.00033) and “mitochondrial
intermembrane space” (p-value = 0.0072) (Supplementary data
excel file). In addition, as outlined in the following section, the
mia40∆ strain was tested because it was implicated as sensitive
to auranofin in a previous study (Lee et al., 2014).
Growth of these five heterozygous deletion strains and the
wild-type (BY4743) strain were monitored in the presence of
different concentrations of auranofin (6.25, 12.5, and 25µg/mL)
in a liquid growth assay. The result indicated that only
three heterozygous deletion strains (mia40∆, acn9∆, and
coa4∆) exhibited drug-induced haploinsufficiency under these
conditions. The growth of these deletion strains was suppressed,
even in the presence of low concentrations of auranofin
(6.25µg/mL) (Figure 3B). However, auranofin does not induce
haploinsufficiency in the other two deletion strains (rad18∆
and nsi1∆) as growth of these strains, in the presence of
auranofin, mimics the pattern observed with the wild-type strain
(Figure 3B). These two deletion strains were not affected possibly
because of the concentration used in our validation studies or
because they may be false positives. For each strain, the growth of
cells (OD600 after 24 h) incubated with auranofin (6.25µg/mL)
was determined in relation to DMSO treatment. The growth of
three heterozygous deletion strains (mia40∆, acn9∆, and coa4∆)
was drastically suppressed by more than 50% in the presence of
auranofin (6.25µg/mL). However, the remaining two deletion
strains (rad18∆ and nsi1∆) had a modest reduction in growth
of∼10% compared to the wild-type strain (Figure 3C).
The growth of these five deletion strains was further confirmed
by spotting serial dilutions of cultures on solid agar. As shown
in Figure 3D, growth of the wild-type and five heterozygous
deletion strains was normal in agar containing DMSO. However,
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FIGURE 3 | Auranofin targets mitochondrial protein(s). (A) Chemogenomic profiling of S. cerevisiae with treatment of auranofin. The strain abundance were
normalized using EdgeR and shown. (B) Growth curve of wild type (BY4743) and heterozygous deletion strains (mia40∆, acn9∆, coa4∆, rad18∆, and nsi1∆) in the
presence of indicated concentration of auranofin in YPD broth were determined. (C) The percent growth of yeast cells (OD600 after 24 h) incubated with auranofin
(6.25µg/mL) in YPD broth was determined in relation to the DMSO treatment. The results are presented as means ± SD (n = 3). Statistical analysis was calculated
using the two-tailed Student’s t-test. P-values (*P ≤ 0.05) (**P ≤ 0.01) are considered as significant. (D) Yeast cells grown in YPD broth overnight were serially diluted
and spotted on solid YPD agar containing auranofin (6.25µg/mL) or DMSO and the CFU were shown. (E) Comparison of Lee et al. (2014) HIP results with our 85
strains are shown as a Venn diagram.
the heterozygous deletion strain,mia40∆, exhibited a nearly two-
fold reduction in colony forming units when spotted onto YPD
agar containing auranofin (6.25µg/mL).
A study conducted by Lee et al. (2014) previously analyzed
a heterozygous deletion pool, representing essential genes,
using haploinsufficiency profiling with hundreds of compounds
including auranofin. Examination of theauranofin-generated
data set shows that they identified 17 strains as possibly sensitive.
Comparison of Lee et al.’s results with our 85 strains showed that
two strains, rho1∆ and mia40∆, overlapped between the data
sets (Figure 3E). An additional study by Gamberi et al. (2015)
specifically assessed sensitivity and resistance of haploid deletion
strains involved in mitochondrial function and found them to
be differentially effects to auranofin compared to the haploid
wild type parental strain. Based on studies by Gamberi et al.
(2015) and Lee et al. (2014), we next moved to examine sensitivity
of the corresponding heterozygous deletion strains involved in
mitochondrial function and redox homeostasis that are possibly
sensitive to auranofin.
Heterozygous deletion strains with genes deleted in
mitochondrial function and redox homeostasis experienced
a significant growth reduction when treated with auranofin
(6.25µg/mL) relative to DMSO-treated cells (Figure 4A–green
and gray bars), including ndil∆, atp2∆, citl∆, sdh4∆, gsh1∆,
gsh2∆, prx1∆, trr1∆, erv1∆, toa2∆, arp7∆, ydl63w∆, and
yjl086c∆. These results are in agreement with Gamberi’s et al.
(2015) results in that mitochondrial function appears to be a
target of auranofin. It should be noted that Gamberi et al. used
haploid deletion strains sensitivity, which generally does not
inform on the direct target of a compound as opposed to the
heterozygous deletion strains used in our study. In addition,
Gamberi et al. examined resistance of haploid deletion strains
and varied media conditions, resulting in their conclusion that
Pos5 was the target—however, several other haploid deletions
strains also demonstrated slight resistance to auranofin and
heterozygous strain sensitivity was not examined. Our results
demonstrate that the heterozygous pos5∆ strain is not sensitive
to auranofin in liquid or agar conditions suggesting Pos5 is
unlikely to be the direct target of auranofin (Figures 4A,B). The
heterozygous strains that were identified by Lee et al. (2014)
were generally not as sensitive in liquid growth compared to
mitochondrial or redox-related strains (Figure 4A—brown
bars). Because this set of strains contained deletions of genes
with a wide variety of functions it is likely that they not specific
hits from the screen and shows the importance of testing
individual strains to confirm sensitivity to auranofin. These
results were confirmed using the YPD agar-spotting assay in
that many strains were not sensitive. Interestingly, heterozygous
deletion strains involved in ROS response and redox homeostasis
(sdh4∆, gsh1∆, gsh2∆, and prx1∆) which had significant growth
reduction in liquid medium did not demonstrate considerable
reduction in growth when spotted onto YPD agar containing
auranofin (6.25µg/mL) (Figure 4B).
As noted earlier, heterozygous deletion strains that encode
genes required for mitochondrial function (including ndil∆,
atp2∆, citl∆, and erv1∆), showed a considerable decrease in
colony count (almost one-fold log reduction) when spotted
onto YPD agar containing auranofin (6.25µg/mL) (Figure 4B).
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FIGURE 4 | Effect of auranofin on deletion strains related to ROS production and mitochondrial function. (A) The percent growth of wild type and
heterozygous deletion strains incubated with auranofin (6.25µg/mL) in YPD broth (OD600 after 24 h) was determined in relation to the DMSO treatment. The results
are presented as means ± SD (n = 3). Statistical analysis was calculated using the two-tailed Student’s t-test. P-values (*P ≤ 0.05) (**P ≤ 0.01) are considered as
significant. (B) Yeast cells grown in YPD broth overnight were spotted on solid YPD agar containing auranofin (6.25µg/mL) or DMSO. The colony forming units are
shown.
Interestingly, a deletion strain (erv1∆), which forms a complex
with Mia40 (Rissler et al., 2005), showed considerable sensitivity
to auranofin, which coincides with Lee et al.’s findings
(Figure 4B). Taken altogether, our results as well as the overlap
with the previous haploinsufficiency profiling (Lee et al., 2014),
supports the notion that Mia40/Erv1 is the probable antifungal
target of auranofin.
Auranofin Inhibits the Import of Mia40
Substrate (Cmc1)
To further confirm the specific inhibition of the Mia40-
Erv1 pathway by auranofin we employed several biochemical
experiments using purified yeast mitochondria similar to
a previous study that investigated the effect of several
small molecule inhibitors of redox-regulated protein import
into mitochondria (Dabir et al., 2013). A possible indirect
mechanism of inhibition of mitochondrial function and the
Mia40-Erv1 pathway is by the disruption of membrane
potential or diminished oxidative phosphorylation. Maintenance
of membrane potential was determined by mitochondrial
uptake of DiSC3 (5) dye and subsequent quenching in the
presence of membrane potential. Auranofin had no effect on
the membrane potential compared to DMSO whereas the
uncoupling agent, CCCP, caused a 4-fold increase in fluorescence
indicating uncoupled mitochondria (Figure 5A). The effect
on mitochondrial respiration was determined by measuring
dissolved oxygen in a chamber with purified mitochondria and
respiration was initiated with NADH resulting in an oxygen
consumption rate (−0.45 O2 nmol/s) consistent with well-
coupled mitochondria. The addition of DMSO did not increase
respiration rate and auranofin at a concentration of 34µg/mL
only slightly increased the respiration rate (−0.64 O2 nmol/s)
(Figure 5B and Table S2). As a control, the addition of CCCP
resulted in a severe increase in consumption rate (−1.15 O2
nmol/s) suggestive of uncoupled mitochondria (Figure 5B).
To confirm that auranofin targets the Erv1/Mia40 pathway we
measured the effect of compound on the import of mitochondrial
protein substrates compared to control compounds previously
identified as Erv1 inhibitors (Dabir et al., 2013). Radiolabeled
precursor proteins were incubated with mitochondria in
the presence of small molecules or DMSO and the reaction
was terminated with protease and subsequently analyzed
by gel electrophoresis. Protein substrates from different
import pathways were assessed including the Tim23 substrate,
Su9-DHFR, and the Mia40 substrate, Cmc1. Auranofin at a
lower concentration of 6.8µg/mL inhibits import of Su-DHFR
to a 60% level and Cmc1 to a 25% level compared to untreated
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FIGURE 5 | Auranofin does not impair general mitochondrial function but inhibits the import of substrates of the Mia40 pathway. (A)Mitochondrial uptake
and quenching of DiSC3(5) dye when membrane potential is present. Dye fluorescence was measured as relative fluorescence units (RFUs) in the presence of DMSO,
auranofin, and CCCP. (B) Respiration of mitochondria was initiated by NADH followed by the addition of auranofin and CCCP. Respiration levels measurements were
performed using an oxygen electrode and rates represent the consumption of O2 nmol/s. (C,D) Radiolabeled proteins Su9-DHFR and Cmc1 were imported into
mitochondria in the presence of varying concentrations of auranofin and MB-7. (E) Non-reducing gel demonstrating the formation of the Cmc1-Mia40 intermediate in
the presence of auranofin, MB-6 and MB-7. (F) Auranofin inhibition of protein import is dependent on in organello mitochondrial Erv1 expression level. Wild-type (WT)
and Erv1 overexpressed (OE) mitochondria were treated with varying concentrations of auranofin and the level of radiolabeled Cmc1 was detected. The asterisk
represents a large complex of unknown composition that is observed in most Mia40 precursor studies. Representative gels have been shown (n = 3).
samples (Figures 5C,D). These results indicate the preferential
activity of auranofin toward inhibiting Cmc1 import compared
to Su9-DHFR, which is expected because Cmc1 is directly
imported by Mia40/Erv1. Strikingly, auranofin exhibits more
potent activity than control compound, MB-7 with a drastic
difference in import efficiency observed between the compounds
at 10µM (6.8µg/mL for auranofin and 8.5µg/mL for MB-7;
Figure 5D). Although auranofin does inhibit Su9-DHFR import
at high concentrations, these results demonstrate the compound
has specificity toward the Mia40 pathway and increased potency
compared to previously identified inhibitors from a large-scale
chemical library screen (Dabir et al., 2013). It is not surprising
that the import of Su9-DHFR is mildly inhibited because
mitochondrial import pathways are interconnected.
Mia40 has previously been demonstrated to form an
intermediate with Cmc1 as part of the import process (Bourens
et al., 2012; Neal et al., 2015). The effect of compounds on the
formation of a disulfide intermediate between Mia40 and Cmc1
was monitored in organello. Auranofin inhibits radiolabeled
Cmc1 from interacting with Mia40 in a similar dose dependent
manner to MB-7 (Figure 5E). The addition of another control,
MB-6, causes the accumulation of the intermediate. In sum,
auranofin inhibits the heterodimer formation of theMia40-Cmc1
intermediate and is a potent inhibitor of the Mia40 import
pathway.
Overexpression of Erv1 in Yeast
Mitochondria Confers Resistance to
Auranofin
To further validate the Mia40 pathway as a target of auranofin,
import of Cmc1 was performed with mitochondria from
WT and Erv1 overexpressing yeast. Erv1 overexpression is
expected to maintain the Mia40 pool in an oxidized state,
which is required for the interaction with substrate proteins
(Mesecke et al., 2005; Dabir et al., 2007) and hence should
be more resistant to auranofin inhibition. As predicted, the
Erv1 overexpressing mitochondria were resistant to auranofin
(3.4µg/mL) treatment as evidenced by the increased level of
Cmc1 (60%) import compared to WT (30%) mitochondria
providing further confirmation of Mia40 as a target (Figure 5F).
In Vivo Efficacy of Auranofin in
C. neoformans Infected C. elegans Model
To investigate if the in vitro antifungal activity of auranofin
translates in vivo, the antifungal efficacy of auranofin was
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examined in a C. neoformans-infected C. elegans animal model.
As shown in Figure 6, treatment of infected C. elegans with
fluconazole, flucytosine, and auranofin, at 8µg/mL, produced
a significant reduction (P ≤ 0.01) in mean fungal load
when compared to the untreated control groups. Strikingly,
C. elegans treated with auranofin (8µg/mL) generated the largest
reduction in C. neoformans CFU (0.87 ± 0.03 log10), followed
by fluconazole (8µg/mL) (0.82 ± 0.03 log10) and flucytosine
(8µg/mL) (0.58± 0.11 log10) (Figure 6).
DISCUSSION
Auranofin has a well-established pharmacological and
toxicological profile that has permitted it to be used for the
treatment of rheumatoid arthritis for more than 30 years
(Bernhard, 1982; Furst et al., 1983). Independent of its
antirheumatic effect, several studies have reported the anti-
infective properties of this drug against important parasitic
and bacterial pathogens including Schistosoma mansoni,
Trypanosoma brucei, Plasmodium falciparum, Entamoeba
histolytica, Staphylococcus aureus, and Streptococcus pneumoniae
(Jackson-Rosario et al., 2009; Debnath et al., 2012; Cassetta
et al., 2014; Harbut et al., 2015; Thangamani et al., 2016a,b).
However, a dichotomy exists regarding the antimicrobial MOA
of auranofin. Debnath et al. (2012) and Harbut et al. (2015)
reported that auranofin exhibits its antimicrobial activity
through the inhibition of the thioredoxin reductase (TrxR)
enzyme in both E. histolytica and S. aureus. However, a recent
crystallographic study conducted by Parsonage et al. (2016)
revealed that auranofin most likely does not bind to the cysteine
residues in TrxR of E. histolytica. Another study, conducted
by our research group, also demonstrated that TrxR is not the
primary target of auranofin in bacteria (Thangamani et al.,
FIGURE 6 | Efficacy of auranofin in C. neoformans-infected C. elegans.
L4-stage worms were infected with C. neoformans and treated with auranofin,
fluconazole, and flucytosine, at a concentration of 8µg/mL. After 24 h, worms
were lysed and plated onto YPD plates to determine the CFU per worm. Each
dot represents average fungal load in each worm per well. The results are
presented as means ± SD (n = 3). Statistical analysis was calculated using the
two-tailed Student’s t-test. P-value (**P ≤ 0.01) are considered as significant.
2016a). We demonstrated that auranofin inhibits multiple
biosynthetic pathways including DNA, protein and cell wall
synthesis in bacteria (Thangamani et al., 2016a). However, the
exact molecular target of auranofin, in bacteria, still remains
unclear.
The FDA’s approval of auranofin as an anti-amoebic agent
opened the door for researchers to examine additional clinical
applications for this drug (Debnath et al., 2012). Recent
studies, including the present work, demonstrate that auranofin
inhibits the planktonic growth of multiple species of fungi
including C. albicans, C. glabrata, C. tropicalis, C. parapsilosis,
C. neoformans, and C. gattii with an average MIC of 4µg/ml
(Stylianou et al., 2014; Fuchs et al., 2016).
In addition to planktonic growth, fungi especially, Candida
spp., are known to form biofilms that are recalcitrant to treatment
with antifungal agents. Fungal cells encased within the biofilm
are resistant to most clinically used antifungals, including azole
drugs, ultimately resulting in treatment failure (Chandra et al.,
2001; Mathé and Van Dijck, 2013; Chandra and Mukherjee,
2015). Biofilm-related C. albicans infections thus pose a major
threat to the public (Mathé and Van Dijck, 2013). Therefore, we
examined the effect of auranofin on adherentC. albicans biofilms.
Our results indicate that auranofin is very effective in disrupting
C. albicans biofilm as this drug is able to reduce the metabolic
activity of fungal cells present within the biofilm by more than
75% (relative to the control groups). Further examination of
C. albicans biofilm using confocal microscopy revealed that
auranofin treatment markedly reduces the number of fungal cells
present in the biofilm compared to the control and treatment
groups (fluconazole and flucytosine). These findings illustrate
that auranofin is a potential candidate for use in treatment of
biofilm-related fungal infections.
After verifying auranofin’s antifungal activity, we proceeded
to investigate the antifungal mechanism of auranofin. To
examine auranofin’s antifungal MOA, chemogenomic profiling
was employed given it is a highly-specific technique to
investigate the target of unknown compounds (Giaever et al.,
2004; Roemer et al., 2012). This technique uses drug-induced
haploinsufficiency, where it causes a strain-specific fitness defect
after treatment with compounds, and thereby aids in identifying
the drug target (Giaever et al., 2004; Roemer et al., 2012).
In our study, chemogenomic profiling of S. cerevisiae with
auranofin identified three heterozygous deletion strains of genes
(mia40∆, acn9∆, and coa4∆) involved inmitochondrial function
were found to be highly susceptible to auranofin. On the
other hand, genes (rad18∆ and nsi1∆) involved in chromatin
function were found to not be affected possibly because of
the concentration used in our validation studies or because
they may be false positives from the profiling data. Our results
are in agreement with Gamberi et al. (2015) indicating the
mitochondrial protein(s) is the potential target of auranofin.
We further confirmed the three heterozygous deletion strains
(mia40∆, acn9∆, and coa4∆) were sensitive to auranofin when
grown in YPD liquid medium with auranofin. Interestingly, only
one deletion strain, mia40∆, was very sensitive to auranofin
in YPD agar containing the drug. Gamberi et al. demonstrated
that another mitochondrial protein, the Pos5 NADH kinase, is
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thought to be the likely target of auranofin because the haploid
deletion strain exhibited resistance. However, our chemogenomic
profiling results did not identify pos5∆ heterozygous deletion
strain as sensitive. When the pos5∆ heterozygous deletion strain
was examined in our study, it was found to be not sensitive
to auranofin. Chemogenomic profiling by Lee et al. also did
not identify the pos5∆ heterozygous deletion strain as sensitive
to auranofin (Lee et al., 2014). We also examined additional
genes reported in Gamberi et al.’s study and found heterozygous
deletion strains involved in mitochondrial function (ndil∆, and
atp2∆) showed moderate susceptibility to auranofin. This aligns
with the results of Gamberi et al. where they observed resistance
to auranofin in haploid deletion strains for these two genes
(Gamberi et al., 2015).
Chemogenomic profiling of 6000 genes in S. cerevisiae is a
non-biased technique and further the gene (mia40) identified
by this method also overlaps with data from Lee et al.
(2014). Auranofin is one of 300 compounds screened using
haploinsufficiency profiling and results from Lee et al.’s study
indicates that mia40 is one of the target genes for auranofin
(Lee et al., 2014). In addition, we also observed that another
deletion strain (erv1∆), which forms a complex with mia40 as
reported in Lee et al.’s study, also showed considerable sensitivity
to auranofin (Rissler et al., 2005).
The Mia40 (mitochondrial intermembrane space import
and assembly protein 40)–Erv1 pathway is mainly involved
in oxidation of several cysteine rich proteins that enter
the mitochondria from the cytoplasm (Rissler et al., 2005;
Banci et al., 2009). These proteins, present in the inner
mitochondrial space, are essential for cell viability and are
functionally linked to the respiratory chain (Rissler et al.,
2005; Bihlmaier et al., 2007). In addition, an ERV1 mutant
strain was shown to be deficient in respiration (Lisowsky,
1992) consistent with the metabolic shift from respiration
to fermentation observed in auranofin treated cells (Gamberi
et al., 2015). Results from the present study indicates that
auranofin does not have a generalized mode of action resulting
in the disruption of membrane potential or respiration and
mitochondrial integrity is maintained in the presence of
the compound. However, auranofin preferentially inhibits the
import of mitochondrial protein substrate Cmc1 which is
directly imported by Mia40/Erv1pathway. Also, overexpression
of Erv1confered resistance to auranofin which is directly noticed
by the increased level of Cmc1 import. Taken together, our
findings support the notion that auranofin preferentially targets
Mia40/Erv1pathway in yeast. It should also be taken into
account the affinity of auranofin to human Mia40 protein.
The central part of the human homolog of Mia40 shares high
sequence identity with most of its eukaryotic analog. However,
Mia40 in yeast differs from its human homolog in one major
respect—yeast Mia40 lacks the N-terminal extension including
a transmembrane region (Banci et al., 2009). Future studies
are needed to examine the affinity and binding of auranofin
to human Mia40 protein. It may be possible that a therapeutic
window exists because human Mia40 is not accessible or
affected by auranofin at the concentrations needed for antifungal
activity.
As reported earlier, in bacteria and parasites the thioredoxin
reductase gene was proposed to be the target of auranofin
(Debnath et al., 2012). Gamberi et al. used homozygous
deletion strains and demonstrated that auranofin does not
displayed resistance to both the mitochondrial thioredoxin
reductase (TRR2) and glutathione reductase (GLR1) genes in
S. cerevisiae (Gamberi et al., 2015). However, the effect of
auranofin on cytoplasmic thioredoxin reductase (TRR1) gene was
not explored in that study (Gamberi et al., 2015). Results from
our investigation indicate that the heterozygous deletion strain
(trr1∆) behaves similar to wild type. We therefore conclude that
auranofin does not target the thioredoxin reductase gene in yeast
which is in agreement with a previous study (Gamberi et al.,
2015).
The genes involved in ROS response (SOD1, GSH1, GSH2, and
PRX1) were also examined in this study. Our results revealed
that heterozygous deletion strains encoding these genes were
sensitive to auranofin when grown in YPD liquid broth but
not in YPD agar containing auranofin. Gamberi et al. through
various experiments demonstrated that auranofin does not elicit
the production of ROS (Gamberi et al., 2015) but some haploid
deletion strains were sensitive suggesting they are selectively
important for resistance to auranofin. Taken together it appears
that the ROS response enzymes are not direct targets but some
enzymes do mediate resistance to inhibitory activity by auranofin
that is not due to generation of ROS.
The final step in our study involved investigating the in vivo
efficacy of auranofin in a C. neoformans-infected C. elegans
animal model. Auranofin significantly reduced the mean fungal
load in worms compared to control groups. Future studies are
needed to test the efficacy of auranofin in an appropriate mouse
model of fungal infection. Altogether, results from our study
suggests that auranofin, with its unique MOA and potent in vivo
antifungal activity, warrants further investigation as an antifungal
agent to combat drug-resistant fungal infections. Auranofin
has advantageous qualities to be repurposed as an antifungal
agent, including oral bioavailability, clinically safe, potent broad-
spectrum fungicidal activity, and the ability to cross blood brain
barrier. The characteristics of auranofin as an antifungal agent
offer a significant improvement over current approaches for
treating fungal infections and provide valuable evidence that
auranofin has significant promise to be repurposed as a novel
antifungal drug.
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